Cargando…

Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective

Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramakrishnan, Sharanya, Kumar, Jeevan, Datta, Suvro Sankha, Radhakrishnan, Vivek, Nair, Reena, Chandy, Mammen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751310/
https://www.ncbi.nlm.nih.gov/pubmed/36531042
http://dx.doi.org/10.3389/fonc.2022.1062296
_version_ 1784850441103736832
author Ramakrishnan, Sharanya
Kumar, Jeevan
Datta, Suvro Sankha
Radhakrishnan, Vivek
Nair, Reena
Chandy, Mammen
author_facet Ramakrishnan, Sharanya
Kumar, Jeevan
Datta, Suvro Sankha
Radhakrishnan, Vivek
Nair, Reena
Chandy, Mammen
author_sort Ramakrishnan, Sharanya
collection PubMed
description Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. The centralized model of CAR-T manufacturing which has emerged as the dominant model in developed nations does not seem well-suited to the needs and realities of the developing economies. In this context, we explore the relative advantages and disadvantages of the two models from a developing nation’s perspective.
format Online
Article
Text
id pubmed-9751310
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97513102022-12-16 Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective Ramakrishnan, Sharanya Kumar, Jeevan Datta, Suvro Sankha Radhakrishnan, Vivek Nair, Reena Chandy, Mammen Front Oncol Oncology Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. The centralized model of CAR-T manufacturing which has emerged as the dominant model in developed nations does not seem well-suited to the needs and realities of the developing economies. In this context, we explore the relative advantages and disadvantages of the two models from a developing nation’s perspective. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9751310/ /pubmed/36531042 http://dx.doi.org/10.3389/fonc.2022.1062296 Text en Copyright © 2022 Ramakrishnan, Kumar, Datta, Radhakrishnan, Nair and Chandy https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ramakrishnan, Sharanya
Kumar, Jeevan
Datta, Suvro Sankha
Radhakrishnan, Vivek
Nair, Reena
Chandy, Mammen
Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
title Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
title_full Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
title_fullStr Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
title_full_unstemmed Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
title_short Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
title_sort should we adopt an automated de-centralized model of chimeric antigen receptor- t cells manufacturing for low-and middle-income countries? a real world perspective
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751310/
https://www.ncbi.nlm.nih.gov/pubmed/36531042
http://dx.doi.org/10.3389/fonc.2022.1062296
work_keys_str_mv AT ramakrishnansharanya shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective
AT kumarjeevan shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective
AT dattasuvrosankha shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective
AT radhakrishnanvivek shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective
AT nairreena shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective
AT chandymammen shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective